Search Results

belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

belong to the super-family of G-protein coupled receptors (GPCR), the major molecular target for drug development allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins for the development Beaulieu group is also actively implicated in translational research and industry collaboration to develop new drugs and drug development technology.

Eric Trinquet shares the inside story behind the development of pH Sense, Revvity’s latest innovation spanning two decades at the intersection of fluorescence chemistry, functional assays, and product development advancing GPCR research. ⸻ Inside This Episode How Eric and his team reimagined rare earth complexes to develop and hit the “overexpression ceiling,” Balanced scientific rigor with the unpredictability of product development photophysics and fluorescence chemistry, Eric transitioned into the GPCR field through hands-on assay development

these benefits are designed to enhance your research experience and keep you informed about the latest developments year • per person • 90% discount *subject to verification Eligibility Criteria ✔ Live and work in a developing country. ✔ Be employed by an institution, university, or company based in a developing country. ✔ Provide Do you offer discounts for students or developing countries? Yes. Members from developing countries can join for $24.99/year.

I have 10 years of experience in the development and management of R&D projects and teams in the field I have developed my expertise in the field of pharmacology and biochemistry of GPCR and the crucial role I developed G.CLIPS biotech's innovative technology as a synthesis of the different knowledge, experiences

About Joshua Gross "I am a neuropharmacologist interested in exploiting GPCR biased signaling to design/develop With my expertise in reward behavior, neurophysiology, GPCR signaling, and preclinical drug development , my lab will strive to develop novel GPCR pharmacotherapies that improve efficacy and minimize side

Monash Institute of Pharmaceutical Sciences (MIPS), a collaborative venture targeting new medicines development and CEO of Phrenix Therapeutics, a biotech spin-out from the Neuromedicines Discovery Centre that is developing particularly in the field of psychiatry, where he has led multiple projects into late stage preclinical development

Raimond Heukers , developed a nanobody platform within the research group and used this platform to develop He currently is focusing on the development of nanobody-based immuno tracers as part of the IMI/EFPIA

Department, Ken Vecchio helping set the foundation for the Nanoengineering Materials Research Center and developing Scientists and Engineers working at the nanoscale, specifically protein engineering and small molecule drug development

Khorana’s lab made early key contributions and developed strategies to express, reconstitute and assay He also went on to discover a “counterion switch” in visual pigments and to develop strategies to assay Tom’s lab also developed an amber codon suppression method to genetically encode unnatural amino acids Early applications included “targeted photo-crosslinking,” and more recently, the parallel development

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based stream is now forming the basis of a new technology-based start-up company, HeptOME , to help screen and develop

Pierre Eftekhari "Clinical physiologist and biologist , with more than 25 years of experience in drug development I have participated and initiated methodologies for development of pharmacologically active anti-GPCR

has over 20+ years of experience working in a drug discovery environment mainly in a specialist assay development His current interests include the development of HTS fluorescence-based kinetic binding assays specifically

You can also collect and store information from your site visitors using input elements like custom forms

You can also collect and store information from your site visitors using input elements like custom forms

You can also collect and store information from your site visitors using input elements like custom forms

Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development within the primary cilium, a tiny antenna-shaped structure at the cell surface with critical links to development Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford

Dr Stagg has served as an expert consultant in the development of adenosine-targeting drugs, several permanent member of the Scientific Advisory Board (SAB) of Surface Oncology, a clinical stage company developing

consultancy and data analysis company supporting pharmaceutical, life science, and academic scientists in the development He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development

Mid-career, he has worked in finance and developed high-frequency trading systems. early-stage medical device start-up and in 5 years was responsible for project R&D and managing a focused development

He has focussed on developing a comprehensive map of ovarian cancer essential genes using whole genome Several of these targets are being developed for potential new therapeutic strategies in ovarian and

Bridge theory to practical drug development decisions?

and experimental systems (purified proteins, cultured cells, model organisms) in combination with the development Our ongoing efforts have direct implications in cancer, embryonic development defects, and neurological

mispronunciations, cultural differences, and the importance of a multidisciplinary approach in drug development discussed their research interests, particularly in the field of GPCR, and the importance of method development discussed their professional backgrounds, highlighting the benefits of a multidisciplinary approach in drug development They also highlighted the importance of method development, integrity, and honesty in scientific research

Work from our lab showed that the PCP components, including ADGRC2 and ADGRC3, are localized in the developing My research focus is the mechanisms of neural circuit development, function and disease." To exploit this expression profile, we have developed antibody-drug conjugates (ADCs) targeting CD97, oncogenesis in glioblastoma, the most common brain malignancy, and chromatin organization in human neural development

discussed the importance of hiring based on differentiation, impact, and interest, the need for workforce development will share notes about PRISM and presentability with Arthur. - Arthur will share the story of PRISM's development Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, significance of fundamental discoveries, the role of biotech, and the need for efficiency and process development They also discussed the disruption within the pharmaceutical sector, the importance of workforce development

discussed the importance of hiring based on differentiation, impact, and interest, the need for workforce development will share notes about PRISM and presentability with Arthur. - Arthur will share the story of PRISM's development Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, significance of fundamental discoveries, the role of biotech, and the need for efficiency and process development They also discussed the disruption within the pharmaceutical sector, the importance of workforce development

They also discussed the ongoing developments in the GPCR field, the upcoming adhesion GPCR consortium He explained that initially, the field lacked adequate tools, and his lab had to develop new techniques Yamina expressed her appreciation for Demet's work and asked about the development of the GPCR field GPCR Field and Naming Convention Discussion Demet and Yamina discussed the ongoing developments in the